TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11514693

Group type: EXPERIMENTAL
Intervention: 5 mg nebulised salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 microg nebulised ipratropium bromide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of salbutamol and ipratropium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 20
Study: 9297994

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0 mg daily)
Number of subjects: 4695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study: 7904411

Group type: EXPERIMENTAL
Intervention: Heliotherapy for 4 weeks
Number of subjects: 95
Study: 3556957

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg every 6 h intravenously and colloidal aluminium phosphate 11 g every 4 h per os
Number of subjects: 31

Group type: COMPARATOR
Intervention: No preventive treatment
Number of subjects: 31
Study: 30322408

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (patients who never achieved drug-free status)
Number of subjects: 60
Study: 26420761

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard anaesthetic treatment (Control)
Number of subjects: 20
Study: 25192393

Group type: EXPERIMENTAL
Intervention: Argentine tango (AT) class, 1 hour twice weekly for 2 years
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no prescribed exercise)
Number of subjects: 10
Study: 22866433

Group type: EXPERIMENTAL
Intervention: Bedside nurse-to-nurse handoff
Number of subjects: 60
Study: 20426834

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 18979878

Group type: EXPERIMENTAL
Intervention: Bryan cervical disc arthroplasty (group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional anterior cervical discectomy and fusion (group B)
Number of subjects: 52
Study: 15868884

Group type: COMPARATOR
Intervention: Linoleic acid diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 0
Study: 12848633

Group type: EXPERIMENTAL
Intervention: Omeprazole, 10 or 20 mg once daily for 4 weeks
Number of subjects: 826

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 826
Study: 10827369

Group type: EXPERIMENTAL
Intervention: Lotrafiban (up to 50 mg twice daily)
Number of subjects: 9200

Group type: COMPARATOR
Intervention: Aspirin (standard therapy)
Number of subjects: 9200
Study: 8890722

Group type: EXPERIMENTAL
Intervention: Thyroxine 25 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroxine 50 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroxine 100 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroxine 150 micrograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no thyroxine administration)
Number of subjects: 0
Study: 8448808

Group type: EXPERIMENTAL
Intervention: Ioxaglate (ionic contrast agent)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Iohexol (nonionic contrast agent)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Nonionic agent (iohexol)
Number of subjects: 500
Study: 3519243

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 75 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed combination tablet containing 5 mg amiloride and 50 mg hydrochlorothiazide (Moduretic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiloride 15 mg/day added to hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiloride reduced to 7.5 mg/day using Moduretic
Number of subjects: 0
Study: 31062629

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 133
Study: 30184553

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study: 26387640

Group type: EXPERIMENTAL
Intervention: Elliptical trainer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic workstations (elliptical trainer and treadmill)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional sitting and standing workstations
Number of subjects: 12
Study: 25566573

Group type: EXPERIMENTAL
Intervention: Topical suspension formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ointment formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical suspension formulation
Number of subjects: 20
Study: 22835597

Group type: COMPARATOR
Intervention: Control (0% DHA)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.32% DHA
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.96% DHA
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.64% DHA
Number of subjects: 141
Study: 21054830

Group type: EXPERIMENTAL
Intervention: Individually tailored information related to social-cognitive determinants of screening (Group B)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Culturally tailored information addressing cultural factors related to screening (Group C)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Generic information on HBV (Group A)
Number of subjects: 10000
Study: 18702951

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 or 30 mg/d for 6 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metformin (500 or 750 mg/d for 6 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aerobic exercise (3-month program)
Number of subjects: 27
Study: 15755330

Group type: EXPERIMENTAL
Intervention: Outreach facilitation intervention
Number of subjects: 90283
Study: 11977431

Group type: EXPERIMENTAL
Intervention: Visual evoked potential (VEP) during acute attack
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potential (BAEP) during acute attack
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Visual evoked potential (VEP) after 7 days post-attack
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potential (BAEP) after 7 days post-attack
Number of subjects: 25
Study: 10584050

Group type: EXPERIMENTAL
Intervention: (15)NH(4)Cl (3.45 mg (15)N*kg(‐)(1)*d(‐)(1))
Number of subjects: 13

Group type: COMPARATOR
Intervention: [(15)N(2)]urea
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: (15)NH(4)Cl (3.9 mg (15)N*kg(‐)(1)*d(‐)(1))
Number of subjects: 13
Study: 8902367

Group type: EXPERIMENTAL
Intervention: DSP-based multichannel EMG acquisition and analysis system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Velocity meter for monitoring muscle activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Software for system initialization and data processing
Number of subjects: 0
Study: 1808500

Group type: EXPERIMENTAL
Intervention: Piracetam (9 g daily) in group I
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 g daily) in group II
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo in both groups
Number of subjects: 28
Study: 6481927

Group type: EXPERIMENTAL
Intervention: Provider continuity
Number of subjects: 776

Group type: COMPARATOR
Intervention: Provider discontinuity
Number of subjects: 776
Study: 31256435

Group type: EXPERIMENTAL
Intervention: Repeated measures model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted repeated measures model with weights from K-means clustering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Score tests with one, two, and three degrees of freedom
Number of subjects: 0
Study: 27794135

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 26854416

Group type: EXPERIMENTAL
Intervention: Patient-Specific Contrast Formula (PSCF) combined with Exponentially Decelerated Contrast Media (EDCM)
Number of subjects: 200
Study: 24989702

Group type: EXPERIMENTAL
Intervention: High sodium diet (HS; 300-350 mmol/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low sodium diet (LS; 20 mmol/day)
Number of subjects: 30
Study: 22544010

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Paliperidone
Number of subjects: 91
Study: 20353859

Group type: EXPERIMENTAL
Intervention: Dorsal padded aluminum splint
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Volar padded aluminum splint
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Custom thermoplastic splint
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no specific splint type)
Number of subjects: 87
Study: 17683107

Group type: EXPERIMENTAL
Intervention: Empathic responsiveness
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Empathy
Number of subjects: 318
Study: 16135859

Group type: EXPERIMENTAL
Intervention: Risperidone (1-6 mg per day)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 11840417

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy agents (gemcitabine, topotecan, liposomal doxorubicin, prolonged oral etoposide) with platinum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 0
Study: 10463522

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 8527263

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg
Number of subjects: 10
Study: 2219256

Group type: EXPERIMENTAL
Intervention: Incubated platelet concentrates (PCs) at 37 degrees C for 1 hour
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-incubated platelet concentrates (PCs) at 22 degrees C for 1 hour
Number of subjects: 15
Study: 877527

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 30832617

Group type: EXPERIMENTAL
Intervention: Olaparib combined with temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) for 6 weeks, followed by Olaparib as a single agent for 4 weeks during the radiotherapy period.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olaparib combined with adjuvant TMZ during the maintenance period.
Number of subjects: 79
Study: 29179649

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 100 million allo-hMSCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 million allo-hMSCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26309226

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Detectable viral load
Number of subjects: 903
Study: 23550906

Group type: EXPERIMENTAL
Intervention: 10 mg UPA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 20 mg UPA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 50 mg UPA
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21717895

Group type: EXPERIMENTAL
Intervention: Osmotic soft tissue expander implanted in the experimental group (10 patients).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Particulated bone graft protected by titanium mesh and collagen membrane in the experimental group.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bone block graft from anterior ramus in the reference group (10 patients).
Number of subjects: 20
Study: 19470552

Group type: EXPERIMENTAL
Intervention: Electrical stimulation superimposed on progressive resistance training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham electrical stimulation superimposed on progressive resistance training
Number of subjects: 32
Study: 17295589

Group type: EXPERIMENTAL
Intervention: Exposure to alcohol-related words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to nonalcoholic beverage words
Number of subjects: 0
Study: 15117982

Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg, intramuscular injection, once monthly)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg, orally, once daily)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg, intramuscular injection, once monthly) in ER+/PgR+ subgroup
Number of subjects: 587

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg, orally, once daily) in ER+/PgR+ subgroup
Number of subjects: 587
Study: 11694699

Group type: EXPERIMENTAL
Intervention: Insulin lispro before breakfast
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Insulin lispro before dinner
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Insulin lispro after meals
Number of subjects: 61

Group type: COMPARATOR
Intervention: Regular human insulin before meals
Number of subjects: 61
Study: 9645801

Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 503

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 503
Study: 8198411

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (500 mg/kg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (30 infants without suspicion of infection)
Number of subjects: 67
Study: 2898256

Group type: EXPERIMENTAL
Intervention: ICI 118,551, 50 mg orally given thrice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31852021

Group type: EXPERIMENTAL
Intervention: PERANTARA (self-help intervention)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 132
Study: 29651872

Group type: EXPERIMENTAL
Intervention: Pilates intervention for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study: 28912210

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: Depressive symptom frequency
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: Stress levels
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: Sadness or depression levels
Number of subjects: 15828

Group type: COMPARATOR
Intervention: Use of evidence-based medications
Number of subjects: 15828

Group type: COMPARATOR
Intervention: Event rates for all outcomes analyzed
Number of subjects: 15828
Study: 26215748

Group type: EXPERIMENTAL
Intervention: 40-hour multidisciplinary vocational rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100-hour multidisciplinary vocational rehabilitation
Number of subjects: 0
Study: 23621289

Group type: EXPERIMENTAL
Intervention: Enteral feeds 80 mL/kg/day started within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day, no intravenous fluids
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravenous fluids 50 mL/kg/day started along with enteral feeds 30 mL/kg/day within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day
Number of subjects: 46
Study: 21073773

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 81
Study: 18394169

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (ASAQ)
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Control group (Chloroquine)
Number of subjects: 1434
Study: 16404409

Group type: EXPERIMENTAL
Intervention: Child-specific definitions of Metabolic Syndrome (MS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Adult definitions of Metabolic Syndrome (MS)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Insulin quartiles
Number of subjects: 99
Study: 14504182

Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin dose ≤100 mg
Number of subjects: 12562

Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin dose 101-199 mg
Number of subjects: 12562

Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin dose ≥200 mg
Number of subjects: 12562

Group type: COMPARATOR
Intervention: Placebo with aspirin dose ≤100 mg
Number of subjects: 12562

Group type: COMPARATOR
Intervention: Placebo with aspirin dose 101-199 mg
Number of subjects: 12562

Group type: COMPARATOR
Intervention: Placebo with aspirin dose ≥200 mg
Number of subjects: 12562
Study: 11778260

Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (NON-SSD)
Number of subjects: 68
Study: 8962903

Group type: EXPERIMENTAL
Intervention: Enteral nutritional support supplement (1680 calories, 294 grams of carbohydrates, 36.9 grams of fat, 43.5 grams of protein in branched chain amino acids)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enteral nutritional support supplement
Number of subjects: 38
Study: 1463361

Group type: EXPERIMENTAL
Intervention: Long course DEC treatment (6, 7, 8, 9 or 10 mg kg‐1 b.w. divided into three doses daily for seven days)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Short course DEC treatment (15 mg kg‐1 b.w. once daily for one, two or three days)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: DEC treatment for Brugia malayi infections
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: DEC treatment for mixed infections
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: DEC treatment for Wuchereria bancrofti infections
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 1015
Study: 6738373

Group type: EXPERIMENTAL
Intervention: Mestranol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31012786

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (R3R)
Number of subjects: 15459

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (R3C)
Number of subjects: 15459

Group type: COMPARATOR
Intervention: Non-malaria control vaccine (C3C)
Number of subjects: 15459

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 15459

Group type: COMPARATOR
Intervention: Non-malaria control vaccine
Number of subjects: 15459
Study: 29315079

Group type: EXPERIMENTAL
Intervention: Spermidine supplementation (1.2 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26573151

Group type: EXPERIMENTAL
Intervention: Wise Nurse educational software
Number of subjects: 37

Group type: COMPARATOR
Intervention: Printed clinical cases (comparison group)
Number of subjects: 37
Study: 25218293

Group type: EXPERIMENTAL
Intervention: ABX196 (0.2, 0.4, and 2.0μg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ABX196 with HBs antigen
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ABX196
Number of subjects: 44
Study: 21610154

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study: 19596163

Group type: EXPERIMENTAL
Intervention: Paricalcitol, 1 mug/d for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 61
Study: 17617289

Group type: EXPERIMENTAL
Intervention: Tizanidine capsule (4 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tizanidine tablet (reference)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tizanidine capsule and tablet
Number of subjects: 18
Study: 15767241

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other statins (atorvastatin, simvastatin, pravastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study: 12231416

Group type: EXPERIMENTAL
Intervention: 800 mg oral clodronate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1600 mg oral clodronate
Number of subjects: 31

Group type: COMPARATOR
Intervention: 30 mg intravenous clodronate
Number of subjects: 31
Study: 10083698

Group type: EXPERIMENTAL
Intervention: Brief advice at the end of the ED consultation to return to their GP for a smear (intervention)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 217
Study: 10150325

Group type: EXPERIMENTAL
Intervention: Atenolol (120 mg/d orally)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d orally)
Number of subjects: 21
Study: 2039377

Group type: EXPERIMENTAL
Intervention: Daily prednisone therapy (1.5 mg/kg per day and 0.75 mg/kg per day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Daily prednisone therapy
Number of subjects: 102
Study: 7434114

Group type: EXPERIMENTAL
Intervention: Intermittent catheterization for urinary drainage in patients with incomplete lesions
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Indwelling catheterization for urinary drainage in patients with complete lesions
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Transcutaneous suprapubic Bonnano (stab) continuous catheter drainage in a random group of 24 male patients with complete neurological lesions
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Bladder outlet operations
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Permanent urinary diversion
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Urodynamic and videoradiological techniques
Number of subjects: 515